about
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo.miRNA-148b regulates radioresistance in non-small lung cancer cells via regulation of MutL homologue 1.Pharmacokinetic evaluation of pemetrexed.EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro.Pemetrexed and bevacizumab-containing chemotherapy for pleomorphic carcinoma of the lung.Protein tyrosine phosphatase PTPRB regulates Src phosphorylation and tumour progression in NSCLC.Silencing miR-21 sensitizes non-small cell lung cancer A549 cells to ionizing radiation through inhibition of PI3K/Akt.miR-21 modulates the effect of EZH2 on the biological behavior of human lung cancer stem cells in vitro.Optimal three-dimensional reconstruction for lung cancer tissues.Examining the effect of gene reduction in miR-95 and enhanced radiosensitivity in non-small cell lung cancer.Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review.A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect.
P2860
Q33404543-E238C73E-21F7-4525-B297-A242ACF58193Q36099282-6C99477D-89AB-4839-BE18-0F25B11AB9F8Q37626837-A9FAA386-74F2-4E23-B719-8EB7C058CB55Q37877715-8BA10900-B9EF-40B8-9859-A919C63C76EFQ38626547-6F50A366-CD3D-4E82-9F29-1DB8CCA65876Q39654382-7D3878EF-95CF-49BC-8805-DEEC772B57D8Q40695460-991C3950-566F-423F-99D6-DB694853BE92Q41220200-ADC62376-C140-41E9-B7CE-D038BB47BD33Q47093759-12CFCD0E-C83F-4EA0-B13B-B7C934BA15CEQ47815936-04C93104-FBF9-4D29-839B-B9D3CFB866C8Q51544354-6B8F27F2-3B70-4EB3-A431-68F139AFBA2BQ52562714-C050EB8C-C56A-4646-AB70-95D605B3870BQ52722993-A565B69C-9F1B-416A-88E0-12B941C05CEAQ55248249-D4BF5095-B478-4638-BEBF-9CE0D9666C4F
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pemetrexed in advanced non-small-cell lung cancer.
@ast
Pemetrexed in advanced non-small-cell lung cancer.
@en
Pemetrexed in advanced non-small-cell lung cancer.
@nl
type
label
Pemetrexed in advanced non-small-cell lung cancer.
@ast
Pemetrexed in advanced non-small-cell lung cancer.
@en
Pemetrexed in advanced non-small-cell lung cancer.
@nl
prefLabel
Pemetrexed in advanced non-small-cell lung cancer.
@ast
Pemetrexed in advanced non-small-cell lung cancer.
@en
Pemetrexed in advanced non-small-cell lung cancer.
@nl
P2093
P2860
P1476
Pemetrexed in advanced non-small-cell lung cancer.
@en
P2093
Alexander D Fuld
James R Rigas
Konstantin H Dragnev
P2860
P304
P356
10.1517/14656566.2010.482560
P407
P577
2010-06-01T00:00:00Z